Neogen’s Q4 Revenue Hits $224.7M, Beats Forecast by 7.2%
Neogen reported Q4 revenue of $224.7 million, down 2.8% year over year yet surpassing analysts’ forecasts by 7.2% while also beating EPS estimates. Shares jumped over 50% post-report, driven by strength in its diagnostic test consumables and animal health product sales.
1. Neogen Q4 Financial Performance
Neogen reported Q4 revenue of $224.7 million, a 2.8% year-over-year decline, but exceeded analysts’ consensus by 7.2% and delivered an EPS beat.
2. Stock Reaction
Shares have rallied approximately 53% since the earnings release, reflecting investor confidence in Neogen’s diagnostic test consumables and animal health product portfolio.
3. Industry Dynamics
Recurring revenue from consumables and maintenance services underpins Neogen’s results, while aging demographics and advances in digital health support future growth despite pricing and regulatory pressures.